The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 5350 participants.
Also called NCT05836987
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 5,350 participants
- Registry
-
NCT05836987
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT05836987. Randomized; single masking; primary purpose prevention. Start 2023-07-13 (actual); primary completion 2029-07-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
- Acronym
- REACT-AF
- Condition
- Atrial Fibrillation
- Intervention (Device)
- AFSW Guided DOAC
- Intervention (Drug)
- Continuous DOAC therapy
- Lead sponsor
- Johns Hopkins University
- Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator
- Northwestern University
Record details
- Record id
cardio:ct-nct05836987- Content hash
a21fd9f6fa247ac0a5bfbe9edb89b6556f8ddf6f2edf4118e144780144178c57